# US 2022/0018782 A1 · Methods for determining viral titre using raman spectroscopy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0018782 A1
- Document ID: US20220018782A1
- Status: Published application
- Kind: A1
- Application number: 17/417,466
- Filed: 2019-12-23
- Published: 2022-01-20
- Earliest claimed: 2018-12-24
- Assignees: Cell Therapy Catapult Limited
- Applicants: Cell Therapy Catapult Limited
- Inventors: John Churchwell; Marc Olivier Baradez; Damian Marshall
- Web page: https://patentgrep.com/patent/US20220018782A1

## CPC

- G01N 21/65: Raman scattering
- G01N 2201/1293: resolving multicomponent spectra
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The use of Raman spectroscopy for the monitoring and assessment of viral titre is disclosed. A method of quantifying viral titre in a sample using Raman spectroscopy, comprises the steps of: (a) providing a sample and irradiating the sample with a light source; (b) measuring the total intensity of Raman scattered light within each one of a plurality of wavenumber ranges to obtain a wavenumber intensity data set for the sample, wherein the plurality of wavenumber ranges are pre-selected and are characteristic of the vims in the sample; (c) performing mathematical data processing steps on the wavenumber intensity data; and (d) quantifying the viral titre based upon the output of the mathematical data processing steps.

## Claims

### Claim 1

A method of quantifying viral titre in a sample using Raman spectroscopy, the method comprising the steps of:
(a) providing a sample and irradiating the sample with a light source;
(b) measuring the total intensity of Raman scattered light within each one of a plurality of wavenumber ranges to obtain a wavenumber intensity data set for the sample, wherein the plurality of wavenumber ranges are pre-selected and are characteristic of the virus in the sample;
(c) performing mathematical data processing steps on the wavenumber intensity data; and
(d) quantifying the viral titre based upon the output of the mathematical data processing steps.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the steps of performing mathematical data processing and quantifying the viral titre comprise:
(i) optionally normalising the wavenumber signal intensity data by pre-processing the signal intensity data using one or more pre-processing analytical methods, such as a first derivative method, a second derivative method, a standard normal variate (SNV) method, a polynomial fitting method, a multi-polynomial fitting method, a mollifier method, a piecewise polynomial fitting (PPF) method or an adaptive iteratively reweighted Penalized Least Squares (airPLS) method;
(ii) obtaining model parameters by applying to the wavenumber signal intensity data a multivariate regression algorithm, such as a partial least squares (PLS) regression algorithm, optionally wherein the PLS algorithm is a nonlinear iterative partial least squares (NIPALS) regression algorithm or a neural network; and
(iii) quantifying the viral titre using the model parameters obtained by applying the multivariate regression algorithm to the signal intensity data.

### Claim 3 (depends on 1, 2)

A method according to claim 1 or claim 2, wherein the light source used to irradiate the sample is a laser and the sample is irradiated with light having a wavelength of 785 nm.

### Claim 4

A method according to any one of the preceding claims, wherein the Raman scattered light is detected using a charge-coupled device (CCD).

### Claim 5

A method according to any one of the preceding claims, wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 5 or more of wavenumber ranges 1 to 28 as listed in Table 1 and wherein the variable importance projection (VIP) is ≥1.00; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 10 or more of wavenumber ranges 1 to 28 as listed in Table 1 and wherein the VIP is ≥1.00; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 15 or more of wavenumber ranges 1 to 28 as listed in Table 1 and wherein the VIP is ≥1.00; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 20 or more of wavenumber ranges 1 to 28 as listed in Table 1 and wherein the VIP is ≥1.00; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 25 or more of wavenumber ranges 1 to 28 as listed in Table 1 and wherein the VIP is ≥1.00; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises all 28 of wavenumber ranges 1 to 28 as listed in Table 1 and wherein the VIP is ≥1.00.

### Claim 6 (depends on 1, 2, 3, 4)

A method according to any one of claims 1 to 4, wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 5 or more of wavenumber ranges 29 to 59 as listed in Table 1 and wherein the variable importance projection (VIP) is ≥1.25; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 10 or more of wavenumber ranges 29 to 59 as listed in Table 1 and wherein the VIP is ≥1.25; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 15 or more of wavenumber ranges 29 to 59 as listed in Table 1 and wherein the VIP is ≥1.25; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 20 or more of wavenumber ranges 29 to 59 as listed in Table 1 and wherein the VIP is ≥1.25; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 25 or more of wavenumber ranges 29 to 59 as listed in Table 1 and wherein the VIP is ≥1.25; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 30 of wavenumber ranges 29 to 59 as listed in Table 1 and wherein the VIP is ≥1.25; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises all 31 of wavenumber ranges 29 to 59 as listed in Table 1 and wherein the VIP is ≥1.25.

### Claim 7 (depends on 1, 2, 3, 4)

A method according to any one of claims 1 to 4, wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 5 or more of wavenumber ranges 60 to 81 as listed in Table 1 and wherein the variable importance projection (VIP) is ≥1.50; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 10 or more of wavenumber ranges 60 to 81 as listed in Table 1 and wherein the VIP is ≥1.50; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 15 or more of wavenumber ranges 60 to 81 as listed in Table 1 and wherein the VIP is ≥1.50; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 20 or more of wavenumber ranges 60 to 81 as listed in Table 1 and wherein the VIP is ≥1.50; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises all 22 of wavenumber ranges 60 to 81 as listed in Table 1 and wherein the VIP is ≥1.50.

### Claim 8 (depends on 5, 6, 7)

A method according to any one of claims 5 to 7, wherein the viral titre measured is lentiviral titre.

### Claim 9 (depends on 1, 2, 3, 4)

A method according to any one of claims 1 to 4, wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 4 or more of the wavenumber ranges 1 to 12 as listed in Table 2 and wherein the VIP is ≥1.00; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured may comprise 6 or more of the wavenumber ranges 1 to 12 as listed in Table 2 and wherein the VIP is ≥1.00; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured may comprise 8 or more of the wavenumber ranges 1 to 12 as listed in Table 2 and wherein the VIP is ≥1.00; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured may comprise 10 or more of the wavenumber ranges 1 to 12 as listed in Table 2 and wherein the VIP is ≥1.00; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured may comprise all 12 of the wavenumber ranges 1 to 12 as listed in Table 2 and wherein the VIP is ≥1.00.

### Claim 10 (depends on 1, 2, 3, 4)

A method according to any one of claims 1 to 4, wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 4 or more of the wavenumber ranges 13 to 22 as listed in Table 2 and wherein the VIP is ≥1.25; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 6 or more of the wavenumber ranges 13 to 22 as listed in Table 2 and wherein the VIP is ≥1.25; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 8 or more of the wavenumber ranges 13 to 22 as listed in Table 2 and wherein the VIP is ≥1.25; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises all 10 of the wavenumber ranges 13 to 22 as listed in Table 2 and wherein the VIP is ≥1.25.

### Claim 11 (depends on 1, 2, 3, 4)

A method according to any one of claims 1 to 4, wherein the plurality of wavenumber ranges in the Raman spectrum which are measured comprises 4 or more of the wavenumber ranges 23 to 30 as listed in Table 2 and wherein the VIP is ≥1.50; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured may comprise 6 or more of the wavenumber ranges 23 to 30 as listed in Table 2 and wherein the VIP is ≥1.50; or wherein the plurality of wavenumber ranges in the Raman spectrum which are measured may comprise all 8 of the wavenumber ranges 23 to 30 as listed in Table 2 and wherein the VIP is ≥1.50.

### Claim 12 (depends on 9, 10, 11)

A method according to any one of claims 9 to 11, wherein the viral titre measured is adeno-associated viral (AAV) titre.

### Claim 13

A method according to any one of the preceding claims, wherein the viral titre measured is physical viral titre.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method according to any one of claims 1 to 13, wherein the viral titre measured is functional viral titre.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method according to any one of claims 1 to 14, wherein the viral titre measured is not the titre of HIV-1 or HIV-1 virus-like particles (HIV-1 VLPs).

### Claim 16

A method according to any one of the preceding claims, wherein the Raman spectroscopy is not surface enhanced Raman spectroscopy.

### Claim 17

A method according to any one of the preceding claims, wherein the sample is a viral culture and the viral titre is quantified from a wavenumber intensity data set obtained from the culture in situ.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method according to any one of claims 1 to 16, wherein the sample is a sample obtained from the culture medium of a viral culture and the viral titre is quantified from a wavenumber intensity data set obtained from the sample.

### Claim 19

A method according to any one of the preceding claims, the method comprising a first step of quantifying the viral titre in the sample at a first time point and one or more further steps of quantifying the viral titre in the sample at later time points, and further comprising measuring the change in viral titre in the sample between time points, wherein each quantifying step is performed by a method according to any one of the preceding claims, preferably wherein each quantifying step is performed by the same method.

### Claim 20 (depends on 19)

A method according to claim 19, wherein viral titre is quantified repeatedly over a time period to provide a measure of the change in viral titre in real time.

### Claim 21 (depends on 19, 20)

A method according to claim 19 or claim 20, wherein the change in viral titre in the sample is used to determine the start phase, the production phase and/or the stationary phase of a viral production process.

### Claim 22

A method according to any one of the preceding claims, wherein the method is used to determine the optimal conditions for a viral production process.

### Claim 23

A method according to any one of the preceding claims, wherein the method is used to assess a process downstream of a viral production process.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method according to any one of claims 1 to 23, wherein the method comprises a step of comparing the viral titre thereby obtained with the viral titre obtained from the same sample by an alternative method, optionally wherein the alternative method is RT-qPCR or p24 ELISA.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method of determining the extent of viral infection in an individual using Raman spectroscopy, the method comprising quantifying viral titre in a sample by performing the method of any one of claims 1 to 16, wherein the sample is a sample which has previously been obtained from the individual.

### Claim 26 (depends on 25)

A method according to claim 25, wherein the sample is a sample of blood, saliva, sputum, plasma, serum, cerebrospinal fluid, urine or faeces.

### Claim 27 (depends on 25, 62)

A method according to claim 25 or claim 62, wherein the viral titre in the sample from the subject is compared with one or more viral titre measurements which have previously been obtained for the infection in the individual, in order to provide a prognosis of the stage of infection in the individual.

### Claim 28

A method of quantifying viral titre in a sample using Raman spectroscopy, the method comprising the steps of:
(a) providing a wavenumber intensity data set for the sample, wherein the data set has been obtained by irradiating the sample with a light source and measuring the total intensity of Raman scattered light within each one of a plurality of wavenumber ranges, wherein the plurality of wavenumber ranges in the Raman spectrum have been selected as characteristic of the virus in the sample;
(b) performing mathematical data processing steps on the wavenumber intensity data; and
(c) quantifying the viral titre based upon the output of the mathematical data processing steps.

### Claim 29 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method according to claim 28, wherein the method is performed according to the steps defined in any one of claims 2 to 27.

### Claim 30

A method of building a multivariate data processing model which is capable of providing a quantification of viral titre in a sample from a Raman spectroscopy wavenumber intensity data set obtained for the sample, the method comprising:
(a) providing the sample and irradiating the sample with a light source;
(b) measuring the total intensity of the Raman scattered light within each one of a plurality of wavenumber ranges to obtain a wavenumber intensity data set for the sample;
(c) obtaining normalised wavenumber signal intensity data by pre-processing the signal intensity data using a pre-processing analytical method, such as a first derivative method, a second derivative method, a standard normal variate (SNV) method, a polynomial fitting method, a multi-polynomial fitting method, a mollifier method, a piecewise polynomial fitting (PPF) method or an adaptive iteratively reweighted Penalized Least Squares (airPLS) method;
(d) obtaining model parameters by applying to the pre-processed signal intensity data a multivariate regression algorithm, such as a partial least squares (PLS) regression algorithm, optionally wherein the PLS algorithm is a nonlinear iterative partial least squares (NIPALS) regression algorithm or a neural network, wherein a calibration is performed wherein the pre-processed signal intensity data are compared with viral titre data obtained for the same sample conditions using non-Raman spectroscopy methods such as qPCR and p24 ELISA;
(e) inferring response values using the model parameters obtained from the pre-processed data; and
(f) performing variable selection, optionally variable importance projection (VIP), and identifying Raman spectral variables; and
(g) optionally performing one or more further rounds of modelling by re-applying steps (d) to (f) and wherein unimportant variables are removed; and
wherein viral titre in a sample is quantified using the model parameters obtained for the identified Raman spectral variables derived from the multivariate data processing model.

### Claim 31

The use of Raman spectroscopy for quantifying viral titre in a sample.

### Claim 32 (depends on 31)

The use according to claim 31, wherein the sample is a viral culture or a sample from a viral culture and the viral titre is quantified based upon measurements of the intensity of Raman scattered light obtained from the sample in situ, wherein the intensity of Raman scattered light is measured from a plurality of wavenumber ranges in a Raman spectrum which are characteristic of the virus in the sample.

### Claim 33 (depends on 32)

The use according to claim 32, wherein the viral titre in the sample is quantified at a first time point and at one or more later time points, and wherein the change in viral titre in the sample between time points is calculated.

### Claim 34 (depends on 33)

The use according to claim 33, wherein the viral titre in the sample is quantified repeatedly to provide a measure of the change in viral titre in real time.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 31, 32, 33, 34)

The use according to any one of claims 31 to 34, wherein the viral titre in the sample is quantified by performing a method according to any one of claims 1 to 16.
